04 September 2016
A report by visiongain, published in August 2016, predicts the world pre-filled injection devices market will generate $6940m in 2020, with rapid sales expansion to 2026. That forecast and others appear in Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 – Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Manufacturers (CMOs) Including BD, Gerresheimer, Aptar Stelmi, Dätwyler, Ypsomed, Catalent and Vetter; Analysis of Products Including Glass and Plastic Syringes, Cartridges, Pen Injectors, Autoinjectors, Safety Systems and Accessories; Assessment of Companies Specialising in Ready-to-Fill Drug Delivery Systems for Vaccines, Insulin and Biological Drugs, Including Clinic- and Home-Based Applications.
That investigation predicts revenues and trends for the overall pre-filled injection devices market. It also shows discussions, analyses, prospects, R&D and revenue forecasts for leading specialists in the US, Europe, and Asia. Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.
The report’s author notes: “Companies in the pre-filled injection devices market will benefit from the main long-term drivers of growth in the pharmaceutical market which will generate in this market. As life expectancy increases and the ageing population increases, there will be a global rise in demand for healthcare pre-filled medical devices. For example, the number of diabetes patients will increase worldwide, leading to a rise in demand for insulin pens, and this trend will be across many disease populations that can benefit from pre-filled medical devices. The global cancer population will increase along with other disease and innovative drugs will be in demand, which will also create a need for manufacturing novel packaging and drug delivery systems that will protect the new treatments. However, this market has high barriers of entry such as the required expertise, and companies that wish to enter this market should aim to take advantage of the shift towards biologics and novel medicines that will need innovative delivery systems."
Visiongain’s updated study covers pre-filled injection device manufacturers from the following four sectors of the industry – pre-filled syringe manufacturers, component manufacturers, pen injector and autoinjector manufacturers, and contract manufacturing organisations (CMOs) providing filling services for pre-filled injection devices (syringes and cartridges).
That new report analyses 25 leading pre-filled injection device manufacturing companies in the US, Europe and Asia. It explores firms’ activities by:
• Analysing pre-filled injection device product portfolios and technologies
• Investigating the status of developmental products, assessing R&D, progress and possibilities
• Providing revenue forecasts for 10 leading companies from 2016 to 2026
• Giving qualitative analyses (SWOT) of leading companies in that industry and market.
• Interviewing an authority in the field, revealing insights on that technology and its future
• Showing qualitative analyses (STEP) of that industry and market.
A selection of the 25 organisations visiongain covers follow. Companies the survey assesses include these leading pre-filled injection device manufacturers:
• Becton, Dickinson, & Co (BD)
Profiles for leading component manufacturers also appear, including these companies:
• Aptar Stelmi
• Dätwyler Holding
• West Pharmaceutical Services.
Discussions of leading pen injector and autoinjector manufacturers also appear, including these firms:
• Owen Mumford
• SHL Group
Profiles of leading contract manufacturing organisations (CMOs) offering pre-filled syringe filling services appear too, including these service providers:
• Hospira One2One
• Vetter Pharma.
Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 analyses organisations well placed to contribute to and benefit from the expected commercial expansion from 2016 to 2026. That investigation adds to visiongain’s reports on industries and markets in healthcare, including studies on pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services. Each year more new and updated studies appear.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth